RT Journal Article
T1 The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
A1 Warrender-Sparkes, Matthew
A1 Spelman, Tim
A1 Izquierdo, Guillermo
A1 Trojano, Maria
A1 Lugaresi, Alessandra
A1 Grand'Maison, François
A1 Havrdova, Eva
A1 Horakova, Dana
A1 Boz, Cavit
A1 Oreja-Guevara, Celia
A1 Alroughani, Raed
A1 Iuliano, Gerardo
A1 Duquette, Pierre
A1 Girard, Marc
A1 Terzi, Murat
A1 Hupperts, Raymond
A1 Grammond, Pierre
A1 Petersen, Thor
A1 Fernandez-Bolaños, Ricardo
A1 Fiol, Marcela
A1 Pucci, Eugenio
A1 Lechner-Scott, Jeannette
A1 Verheul, Freek
A1 Cristiano, Edgardo
A1 Van Pesch, Vincent
A1 Petkovska-Boskova, Tatjana
A1 Moore, Fraser
A1 Kister, Ilya
A1 Bergamaschi, Roberto
A1 Saladino, Maria Laura
A1 Slee, Mark
A1 Barnett, Michael
A1 Amato, Maria Pia
A1 Shaw, Cameron
A1 Shuey, Neil
A1 Young, Carolyn
A1 Gray, Orla
A1 Kappos, Ludwig
A1 Butzkueven, Helmut
A1 Kalincik, Tomas
A1 Jokubaitis, Vilija
A1 MSBase study group, 
K1 MSBase
K1 Multiple sclerosis
K1 disease-modifying therapy
K1 fingolimod
K1 medication persistence
AB We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p Following the availability of fingolimod, patients were more likely to discontinue injectable treatments. Those who switched to fingolimod were more likely to do so for convenience. Persistence was improved on fingolimod compared to other medications.
YR 2015
FD 2015-07-21
LK http://hdl.handle.net/10668/10005
UL http://hdl.handle.net/10668/10005
LA en
DS RISalud
RD Apr 11, 2025